Methodologies and Formative Work for Combination HIV Prevention Approaches (R21)
Grant Amount: The NIMH intends to commit approximately $1,500,000 in FY 2014 to fund 6-8 awards from this FOA and the companion FOAs; the NIAID intends to commit approximately $206,250 in FY 2014 towards this FOA.
This FOA invites applications to advance science that is needed for optimal HIV combination prevention intervention approaches. Recent advances in biomedical interventions with critical behavioral aspects (e.g., Pre-exposure Prophylaxis [PrEP], Treatment as Prevention) have changed how HIV prevention and treatment are conceptualized. Significant local, city, state, and federally funded efforts are shifting towards community-level interventions to reduce HIV incidence, and these efforts are informed by recent advances regarding: the importance of treatment uptake and retention in care; the effectiveness of combined behavioral and biomedical interventions; and the need to implement interventions community-wide for optimal public health impact. Reductions in HIV incidence will only be achieved through implementation of combinations of interventions that include biomedical and behavioral interventions, as well as components that address social, economic, and other structural factors that influence HIV prevention and transmission. However, combined prevention intervention approaches rely on synergies of multiple elements that can be challenging to design, implement, and evaluate. This initiative will support methodological, formative, and implementation research designed to better understand the processes and outcomes of combination intervention efforts, and that will enhance the implementation of these interventions.
The R21 mechanism is intended to encourage new exploratory and developmental research projects. For example, such projects could assess the feasibility of a novel area of investigation or a new experimental system that has the potential to enhance health-related research. Another example could include the unique and innovative use of an existing methodology to explore a new scientific area. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.
National Institute of Allergy and Infectious Diseases Division of Intramural Research US Department of Health and Human Services Public Health Services National Institutes of Health National Institute of Mental Health
City Agencies Colleges/Universities Commercial Organizations Community Based Organizations County Agencies Educational Organizations/Institutions Federal Government Agencies International Agencies IRS 501 (c)(3) Organizations Nonprofit Organizations Religious Organizations Schools State Agencies Tribal Organizations
Award Amount Notes
The NIMH intends to commit approximately $1,500,000 in FY 2014 to fund 6-8 awards from this FOA and the companion FOAs. The NIAID intends to commit approximately $206,250 in FY 2014 towards this FOA. Future year amounts will depend on annual appropriations.
Behavioral Research Clinical Research Community Health Services HIV/AIDS Prevention Medical Treatments and Therapies Social Services
Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the “Apply for Grant Electronically” button in this FOA or following the directions provided at Grants.gov.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide (http://grants.nih.gov/grants/funding/424/SF424_RR_Guide_General_Adobe_VerB.pdf), except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
Companion Funding Opportunity: RFA-MH-14-180, R01 Research Project Grant; RFA-MH-14-182, R34 Clinical Trial Planning Grant Program.
Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.